New Antiviral Chewing Gum Made From Lablab Beans Shows Strong Virus-Neutralizing Potential in Lab Tests

Researchers at the University of Pennsylvania have developed a next-generation antiviral chewing gum made from lablab beans (Lablab purpureus). These beans contain a unique protein called FRIL, which has demonstrated the ability to “trap” and neutralize several common viruses. This discovery represents an important step toward creating simple tools that can reduce viral transmission through saliva and the oral cavity.

1. FRIL – A Powerful Virus-Binding Protein

The new chewing gum is built around FRIL (favin-related lectin), a naturally occurring protein in lablab beans. According to studies published on PubMed and reports from the University of Pennsylvania, FRIL can bind to and deactivate the glycoprotein envelopes of viruses, preventing them from entering human cells.

Laboratory experiments have shown:

• Over 95% of influenza viruses (H1N1, H3N2) were neutralized

• Approximately 75–94% of herpes viruses (HSV-1, HSV-2) were inactivated

Sources: Penn Dental Medicine, PubMed, ScienceDaily

These findings highlight FRIL’s broad antiviral activity against viruses commonly transmitted through saliva.

---

2. Clinically-Grade Production and Safe for Use

The antiviral gum is manufactured at a clinical-grade standard, meaning it meets the purity and safety levels used in medical research.

Key findings reported by ScienceAlert and IFLScience include:

• Safe to chew and non-irritating

• FRIL remains stable for nearly 800 days at room temperature

• FRIL is released into simulated saliva within just 15 minutes of chewing

This exceptional stability and safety profile make the gum a promising tool for reducing viral transmission in everyday settings.

---

3. Potential Real-World Applications

Scientists suggest the gum could be useful in environments with high risk of viral spread, such as:

• Schools

• Office workplaces

• Public transportation

• Crowded public areas

According to PR Newswire and ScienceDaily, chewing the gum may significantly reduce viral load in the mouth, thus lowering the chances of releasing infectious viral particles through talking, breathing, coughing, or sneezing.

---

4. Research Still in Early Stages (In Vitro)

Despite the impressive results, the research is still in its early stages:

• Current experiments were performed only in vitro (in the lab).

• No large-scale human clinical trials have been conducted yet.

• Experts emphasize that the gum cannot replace vaccines or proven antiviral treatments.

This caution is reinforced by reputable sources such as:

• PubMed

• Cleveland Clinic

• ScienceAlert

More studies, especially clinical trials, are needed before the gum can be approved for widespread use.

---

5. A Promising Advance — But Not a Miracle Cure

The lablab-bean antiviral chewing gum is an exciting breakthrough in virus-prevention research. It offers hope for a simple, affordable, and accessible method to help reduce the spread of influenza and herpes viruses.

However:

• It is not a replacement for medical treatment or vaccination.

• At best, it may serve as a supportive tool—if future human trials confirm its real-world effectiveness.

---

Conclusion

The antiviral chewing gum made from lablab beans represents a promising fusion of biotechnology and natural plant compounds. With its strong virus-neutralizing performance in laboratory tests, it could become a useful tool for reducing viral transmission in the community. Still, much more clinical evidence is required before it can be officially adopted for public use.